That Bavi performed as expected and that the future Bavi trials will be solely combined with other IO agents.
The interim analysis showed that the bavituximab combination group is performing as expected according to the original trial assumptions in terms of overall survival,
we have not seen anything in this trial result that diminishes our enthusiasm for advancing our immuno-oncology (I-O) combination trials. The I-O combination studies are based on different mechanistic synergies that are clearly separate from the chemotherapy combination being evaluated in the SUNRISE study.
Market Data 
Markets 
AI
